Literature DB >> 11918724

Drug specific cytotoxic T-cells in the skin lesions of a patient with toxic epidermal necrolysis.

Amal Nassif1, Armand Bensussan, Guillaume Dorothée, Fathia Mami-Chouaib, Nicolas Bachot, Martine Bagot, Laurence Boumsell, Jean-Claude Roujeau.   

Abstract

Toxic epidermal necrolysis is an extremely severe drug reaction, manifesting itself by widespread apoptosis of keratinocytes, generally considered to result from Fas/CD95-FasLigand interaction, but of unknown primary mechanism. We looked at the role of cells present in the skin blisters as probable effectors of this immune reaction. In a patient suffering from cotrimoxazole-induced toxic epidermal necrolysis, blister fluid cells were phenotyped by FACS and tested without prior restimulation for cytotoxicity on autologous and allogeneic cells in the presence of the drug. Blister fluid lymphocytes were predominantly CD8+, DR+, CLA+, CD56+ T lymphocytes, perforin positive and expressing preferentially two Vbeta chains of the T cell receptor repertoire. These lymphocytes were cytotoxic only in the presence of the drug towards autologous EBV transformed lymphocytes and towards allogeneic cells sharing HLA-Cw4. Cytotoxicity occurred in the presence of either cotrimoxazole, sulfamethoxazole, or the nitroso metabolite of sulfamethoxazole, but not with the hydroxylamine metabolite of sulfamethoxazole. The lysis was blocked by an anti-MHC class I monoclonal antibody. It was abolished by EGTA and CMA, but neither by anti-fas, brefeldin A, nor by anti-TRAIL receptor monoclonal antibodies, strongly suggesting perforin/granzyme-mediated cytotoxicity, without implication of Fas or TRAIL at this stage. This is direct evidence that T lymphocytes present within the lesions of toxic epidermal necrolysis may exhibit, without any re-stimulation, a drug-specific cytotoxicity against autologous cells. Harboring the markers of classical CTL and MHC class I restriction these lymphocytes reacted against the parent drug and one of its reactive metabolites. These results challenge several current concepts and could support new therapeutic approaches.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11918724     DOI: 10.1046/j.1523-1747.2002.01622.x

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  58 in total

Review 1.  Role of bioactivation in drug-induced hypersensitivity reactions.

Authors:  Joseph P Sanderson; Dean J Naisbitt; B Kevin Park
Journal:  AAPS J       Date:  2006-02-03       Impact factor: 4.009

Review 2.  The role of T cells in drug reaction.

Authors:  Andrea Cavani; Ornella De Pità
Journal:  Curr Allergy Asthma Rep       Date:  2006-02       Impact factor: 4.806

3.  Clinical Pharmacogenetics Implementation Consortium guidelines for HLA-B genotype and carbamazepine dosing.

Authors:  S G Leckband; J R Kelsoe; H M Dunnenberger; A L George; E Tran; R Berger; D J Müller; M Whirl-Carrillo; K E Caudle; M Pirmohamed
Journal:  Clin Pharmacol Ther       Date:  2013-05-21       Impact factor: 6.875

Review 4.  Delayed drug hypersensitivity: models of T-cell stimulation.

Authors:  Jacqueline Adam; Werner J Pichler; Daniel Yerly
Journal:  Br J Clin Pharmacol       Date:  2011-05       Impact factor: 4.335

5.  Localised bullous eruptions and epidermal detachment from the extravasation of hydroxyethyl starch (Voluven).

Authors:  James London; Stan Tay; Brigid Brown; Chasari Tancharoen
Journal:  BMJ Case Rep       Date:  2014-12-22

Review 6.  Hypersensitivity reactions to HIV therapy.

Authors:  Mas Chaponda; Munir Pirmohamed
Journal:  Br J Clin Pharmacol       Date:  2011-05       Impact factor: 4.335

7.  Hepatotoxicity associated with long- versus short-course HIV-prophylactic nevirapine use: a systematic review and meta-analysis from the Research on Adverse Drug events And Reports (RADAR) project.

Authors:  June M McKoy; Charles L Bennett; Marc H Scheetz; Virginia Differding; Kevin L Chandler; Kimberly K Scarsi; Paul R Yarnold; Sarah Sutton; Frank Palella; Stuart Johnson; Eniola Obadina; Dennis W Raisch; Jorge P Parada
Journal:  Drug Saf       Date:  2009       Impact factor: 5.606

Review 8.  Amniotic membrane transplantation as a new therapy for the acute ocular manifestations of Stevens-Johnson syndrome and toxic epidermal necrolysis.

Authors:  Elizabeth Shay; Ahmad Kheirkhah; Lingyi Liang; Hossam Sheha; Darren G Gregory; Scheffer C G Tseng
Journal:  Surv Ophthalmol       Date:  2009-08-21       Impact factor: 6.048

9.  Harvesting candidate genes responsible for serious adverse drug reactions from a chemical-protein interactome.

Authors:  Lun Yang; Jian Chen; Lin He
Journal:  PLoS Comput Biol       Date:  2009-07-24       Impact factor: 4.475

10.  SePreSA: a server for the prediction of populations susceptible to serious adverse drug reactions implementing the methodology of a chemical-protein interactome.

Authors:  Lun Yang; Heng Luo; Jian Chen; Qinghe Xing; Lin He
Journal:  Nucleic Acids Res       Date:  2009-05-05       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.